Draft NIST Guidance Highlights Supply Chain Fundamentals as Key Practices in Cyber Supply Chain Risk Management
Client Alert | 1 min read | 02.21.20
Last week, the National Institute of Standards and Technology (NIST) published the draft NISTIR 8276 “Key Practices in Cyber Supply Chain Risk Management” providing Key Practices and related recommendations for monitoring, controlling, and understanding how to conduct cyber – supply chain risk management (C-SCRM). The Eight Key Practices are general and apply equally, in practice, to both traditional supply chain management and C-SCRM, including:
- Integrating SCRM across the organization,
- Understanding the organization’s supply chain, and
- Assessing and monitoring SCRM throughout the supplier relationship.
Specific guidance includes, among others:
- Increasing Board involvement in C-SCRM;
- Understanding the cyber relationship with suppliers, including whether they process critical data; and
- Using third-party assessments to evaluate suppliers.
The guidance should serve to remind organizations of the need to know their supply chain well and to have a purposeful approach to its management. Organizations have an opportunity to comment on this draft guidance until March 4, 2020.
Contacts

Partner and Crowell Global Advisors Senior Director
- Washington, D.C.
- D | +1.202.624.2698
- Washington, D.C. (CGA)
- D | +1 202.624.2500
Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Client Alert | 9 min read | 11.17.26
Priorities and Prospects for AI Legislation in the New Congress
Client Alert | 8 min read | 11.16.26
OCC’s AI Examiner Framework: How Banks’ AI Use Can Trigger Legal Liability and Supervisory Exposure
Client Alert | 3 min read | 11.13.26
Massachusetts Trade Secret Preliminary Injunctions: Prove the Harm, Tailor the Relief

